drugset / Trial / NCT00822341
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
TG-0054 is a CXCR4 antagonist with stem cell mobilization effect as proven in animal model, this is the fist in human study to investigator the safety, tolerability and PK/PD in healthy subjects.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG-0054 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 0.14 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 0.28 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 0.56 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 1.12 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 2.24 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 3.14 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 4.4 mg/kg | Intravenous |
Indications
No indication recorded.